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Susanne Matthes-Martin,1 Ulrike P€otschger,2 Ronald Barr,3 Manuel Martin,1
Heidrun Boztug,1 Thomas Klingebiel,4 Andishe Attarbaschi,1 Werner Eibler,1 Georg Mann1The overall costs of pediatric stem cell transplantation (SCT), including donor search and costs during the
first year post-SCT, were calculated in a cohort of 141 consecutive children undergoing SCT in a single in-
stitution. Costs were correlated with patient and transplantation characteristics and with a risk score for
transplantation-related mortality. Cost-effectiveness was calculated based on the overall cost per surviving
patient. Life-years gained were extrapolated from overall survival, and the costs per expected life-year gained
were calculated. The overall median cost wasV136,382 (175,815$), with awide range, ofV26,897 (34,679$)
to V601,348 (775,343$). Increased costs were significantly associated with age, use of donors other than
matched siblings, and advanced disease. There was a strong correlation of costs with a simple transplanta-
tion-related mortality risk score; median total costs were V89,550 (115,463$) for a score of 0, V127,349
(164,179$) for a score of 1, V156,578 (201,861$) for a score of 2, and V274,915 (354,499$) for a score
of 3 (P\ .001). Cost-effectiveness decreased with increasing transplantation-related mortality risk score;
costs per survivor increased from V93,209 (120,200$) for a score of 0 to a maximum of V1,216,348
(1,568,579$) for a score of 3. Costs associated with pediatric SCT vary substantially; however, the combi-
nation of variables such as age, disease, and donor type is predictive of costs and cost-effectiveness. Costs
per life-year gained are within the broadly accepted range in life-threatening hemato-oncologic diseases, even
in the most cost-intensive patient cohort.
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Growing economic pressure on the public health
care system on the one hand and incrementally expen-
sive therapies on the other hand oblige oncologists to
be aware of the amount of money spent in attempting
to cure patients and to justify the costs of resource-
intensive interventions [1,2]. Government agencies
and insurance companies not only are interested in the
actual overall costs for certain interventions but also
are increasingly demanding data on cost-effectiveness.1Department of Pediatrics, St Anna Children’s Hospital,
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/$36.00
6/j.bbmt.2012.04.002In this context, the costs of allogeneic stem cell
transplantation (SCT) have been evaluated by various
centers [3-8]. SCT is a well-established and potentially
curative approach in patients with high-risk or relapsed
leukemia, primary immunodeficiencies, and severe
aplastic anemia and is considered a resource-intensive
therapy [9].
In contrast to the well-defined costs per treatment
course for expensive novel cancer therapies, the costs
of SCT are difficult to determine. This is related in
part to the complexity of SCT, which involves various
departments (eg, transplantation ward, intensive care
unit [ICU], outpatient clinic, radiation clinic, cell
collection unit, cell processing unit) and different
laboratories. Moreover, pediatric SCT recipients are
an extremely heterogeneous group, with varying un-
derlying malignant and nonmalignant diseases and
wide-ranging toxic and infectious pretransplantation
morbidities. Other variables, including donor type,
graft source, conditioning regimen, various unpredict-
able posttransplantation complications, and need for
medical care during the first year post-SCTand the fre-
quent need for readmission, complicate cost analyses.
In the present study, we aimed to evaluate (1) the
actual costs associated with SCT in an Austrian public1533
Table 1. Patient andTransplantationCharacteristics (n5 141)
Age, years, median (range) 10.5 (0.2-24.8)
Second SCT, n (%) 15 (11)
Diagnosis, n (%)
ALL 49 (35)
Acute myelogenous leukemia 17 (12)
Chronic myelogenous leukemia 7 (5)
Myelodysplastic syndrome 4 (3)
Solid tumor 7 (12)
Lymphoma 5 (4)
Severe aplastic anemia 4 (3)
Fanconi anemia 10 (7)
Hemoglobinopathy 16 (11)
Immunodeficiency 19 (13)
Metabolic disease 3 (2)
Donor, n (%)
Matched sibling donor 46 (33)
Matched unrelated donor 82 (58)
Haploidentical family donor 13 (9)
Type of graft, n (%)
Bone marrow 95 (67)
Peripheral blood stem cells 41 (29)
UCB 5 (4)
1534 Biol Blood Marrow Transplant 18:1533-1539, 2012S. Matthes-Martin et al.hospital, including costs for donor search, graft acqui-
sition, recipient workup, and treatment during the first
year post-SCT, compared with the sum of credit
points allocated by the public health system for one
SCT; (2) factors known before SCT that might be cor-
related with costs, making the costs of individual SCT
predictable; and (3) the cost-effectiveness of pediatric
SCT. Cost-effectiveness calculations are used mainly
to compare 2 different treatment modalities for a given
clinical situation [10]. In several malignant and non-
malignant diseases in pediatric patients, SCT is the
only curative approach, which makes any comparison
to alternative approaches (eg, palliative treatment)
cynical. However, in the context of the actual discus-
sions on cost thresholds for cancer therapies, we
were interested in the costs of pediatric SCT per life-
year gained compared with established therapies for
other diseases [11,12].Conditioning regimen, n (%)
Myeloablative 70 (50)
Reduced-intensity 71 (50)
Major transplantation-associated complications, n (%)
Acute GVHD grade III-IV 15 (11)
Veno-occlusive disease 3 (2)
Rejection/graft failure 18 (13)
Viremia 64 (45)
Hemorrhagic cystitis 6 (4)
Invasive aspergillosis 5 (4)
TRM 27 (19)METHODS
The costs of treatment up to 1 year posttransplanta-
tion were evaluated retrospectively in 150 consecutive
allogeneic SCTs performed between 2004 and 2009
at St Anna Children’s Hospital, Vienna. Nine SCTs
were excluded from the analysis because of incomplete
cost documentation for the first year post-SCT. The
median observation time was 4.5 years. Patient and
transplantation characteristics are presented inTable 1.
All patients included in the analysis were followed
in our SCT outpatient clinic for at least 1 year after
transplantation and were readmitted to the SCT
ward if necessary. For patients who died within the first
year posttransplantation, the costs until the time of
death were calculated. Costs were documented in 2
categories: (1) overhead costs per diem in the trans-
plantation unit, ICU, or outpatient clinic and (2) indi-
vidual patient costs during the first year after SCT.Overhead Costs
Overhead costs were evaluated by step-down re-
gression analysis using the hospital’s 2008 cost-
accounting system for the SCT ward, the ICU, and
the outpatient clinic. The overhead costs included
costs for human resources, housekeeping, mainte-
nance, sterile nursing devices and disposable devices,
parenteral nutrition, saline infusions, and supportive
medications of\V5 per patient per day, as well as rou-
tine laboratory diagnostic tests, including viral and
bacterial surveillance, fluorescence-activated cell sort-
ing analysis, and chimerism testing, which were per-
formed according to a uniform protocol. The average
per diem cost per patient wasmultiplied by the number
of days on which a single patient was treated in one of
the respective departments.Individual Costs
Individual costs were calculated bottom up, by col-
lecting detailed information on chemotherapy,
irradiation, antibody therapy, individual medications,
surgical intervention, radiodiagnostics, and blood
products from the patient charts, based on the prices
detailed by our cost-accounting system for 2008. Be-
cause conditioning regimens and most of the individ-
ual medications were charged on the basis of the
actual amount delivered, which correlates with patient
weight, for each substance, the price per kilogram of
body weight was multiplied by the individual patient’s
weight and the number of days given. Oral medica-
tions prescribed by the outpatient clinic were not in-
cluded in the analysis.
HLATyping, Donor Search, and Graft
Acquisition
Thecosts ofHLAtyping, donor search, andgraft ac-
quisitionwere stratifiedaccording to donor type.Forpa-
tients with family donors, the costs ofHLA typing of the
patient plus family members and the costs of one bone
marrow collection were calculated. For transplantations
from unrelated donors, the costs of unrelated donor
search, including HLA typing and graft acquisition,
were calculated. For haploidentical transplantations,
the costs of peripheral blood stem cell harvest plus the
median costs of T cell depletion were added.
Table 2. Details of Overall Costs per Transplantation for 141 Pediatric SCT Recipients
Mean, V ($) Median, V ($) Range, V ($)
Overhead, SCTward 63,817 (82,281) 57,264 (73,828) 12,526 (16,149)-259,480 (334,528)
Overhead, ICU ward (n 5 27) 36,600 (47,185) 29,847 (38,478) 1930 (2,487)-108,392 (139,727)
Overhead, outpatient clinic 1065 (1,373) 821 (1,058) 96 (123)-3869 (4,987)
HLA typing 8674 (11,181) 10,654 (13,733) 2209 (2,847)-39,572 (51,010)
Graft and graft processing 11,729 (15,119) 16,165 (20,837) 1268 (1,634)-35,280 (45,482)
Diagnostic procedures 31,256 (40,293) 29,096 (37,508) 2031 (2,617)-107,260 (138,256)
Individual medications 22,063 (28,437) 14,170 (18,263) 546 (703)-132,870 (171,242)
Blood products 15,841 (20,415) 8147 (10,499) 190 (244)-115,270 (148,555)
Biol Blood Marrow Transplant 18:1533-1539, 2012 1535Costs and Cost-Effectiveness of Pediatric SCTStatistics
The impact of patient and transplantation charac-
teristics, including age, disease stage, donor type, con-
ditioning regimen, graft type, and previous
transplantation, on costs per patient was analyzed us-
ing the Wilcoxon 2-sample test [13]. Robust regres-
sion was used to simultaneously investigate the
impact of these characteristics on costs per patient
[14]. The correlation of costs with the (previously pub-
lished) TRM risk score was analyzed using the
Kruskal-Wallis test [13,15]. Overall survival was
evaluated by Kaplan-Meier analysis with the log-rank
test [13]. A P value\.05 was considered significant.
The life expectancy of a pediatric population can-
not be determined directly. Thus, for the calculation
of cost-effectiveness, a Weibull mixture cure model
was used to estimate the proportion of cured individ-
uals and the mean survival time of those not cured
[16,17]. These estimates, along with an assumed
additional 60 life-years for cured individuals, were
used to estimate the anticipated life expectancy. Total
costs per patient were divided by the life expectancy
and the cure rate to estimate the total costs per year
of life saved and per cured patient, respectively.RESULTS
Overall Costs of Pediatric SCT
The mean cost of pediatric SCT was V163,174
(210,272$) (median, V136,382 (175,747$)) with an ex-
tremely wide range, from V26,897 (34,658$) to
V601,348 (774,875$). The major proportion of the
cost was related to hospital days (43%), followed by
costs for diagnostic procedures, including routine lab-Table 3. Impact of Patient and Transplantation Characteristics on
Median costs/SCT, V
2nd or 3rd vs 1st SCT 151,977 vs 135,726
Malignant vs non-malignant disease 146,626 vs 123,243
Advanced vs standard disease 127,349 vs 212,085
Haploidentical vs unrelated donor 149,295 vs 134,849
Unrelated vs matched sibling donor 160,855 vs 100,121
Peripheral bood stem cells vs bone marrow 149,295 vs 127,499
Age >10 years vs < 10 years 148,121 vs 131,859
Myeloablative vs reduced intensity conditioning 146,977 vs 134,844oratory tests (19%); individual medications, including
the conditioning regimen (13%); HLA typing plus
graft acquisition (12%); and blood products (10%).
Twenty-seven patients required readmission to the
ICU. Details of the overall costs associated with the
141 SCTs are provided in Table 2.Overall Costs in Relation to Reimbursement by
the Public Health System
The reimbursement of public hospitals by the pro-
vincial health funds is based on a modified system of
diagnosis-related groups, with a specific number of
credit points allocated to each defined medical inter-
vention. The cost calculations for our study cohort
were based uniformly on the prices for 2008. The hos-
pital received 186,747 credit points per SCT, with
a monetary value of V0.83 (1$) per credit point. This
translated into a reimbursement of V155,000
(199,729$) per SCT compared with a mean real cost
of one SCT of V163,174 (210,262$), representing an
average deficit of V8,174 (10,533$).Correlation of Patient and Transplantation
Characteristics with Overall Costs
We restricted our analysis to patient and trans-
plantation characteristics known before SCT to evalu-
ate the predictability of the cost of an individual SCT.
On univariate analysis, age .10 years (median,
V148,121 (190,885$) versus V131,859 (169,935$);
P 5 .021), advanced disease (V212,085 (273,327$) vs
V127,349 (164,107$); P 5 .003), and an alternative
donor (V156,715 (201,949$) versus V102,963
(132,680$); P5 .001) had an apparent impact on over-
all costs.Overall Costs and Costs per Surviving Patient
Maximum costs/SCT, V Costs per surviving patient, V
601,348 vs 307,468 358,987 vs 227,813
601,348 vs 519,799 285,897 vs 171,203
601,348 vs 408,686 803,933 vs 180,122
519,799 vs 601,348 419,581 vs 307,734
601,348 vs 206,030 307,734 vs 121,855
601,348 vs 486,790 324,276 vs 208,044
601,348 vs 338,572 284,668 vs 192,287
484,644 vs 601,348 249,813 vs 226,898
Table 4. Impact of Patient and Transplantation Characteristics on Overall Costs of SCT, Multivariate Analysis
Parameter
Estimate
(Costs V)* SE** 95% Confidence Limits Chi-Square p-value***
Intercept 74010 32911 9506 138515 5.06 0.025
Second or third SCT 23355 15461 233657 26947 0.05 0.828
Malignant disease 2500 14524 225967 30967 0.03 0.863
Advanced disease 51290 11479 28792 73788 19.97 <.0001
Haploidentical donor 41149 20453 1061 81236 4.05 0.044
Unrelated donor 63467 9926 44013 82921 40.89 <.0001
Peripheral blood stem cells 1832 11528 220761 24426 0.03 0.874
Age > 10 years 32637 8862 15269 50006 13.56 0.0002
Myeloablative conditioning 3813 12976 221620 29245 0.09 0.769
The intercept represents the baseline costs for each patient, i.e. the average cost of patients without risk factors ( 74.000 Euro). An additive score that
is based on the estimates for each risk factor can be used to predict the average overall costs taking into account his risk-profile.
*The parameter estimate of the linear robust regression model represent the estimated increase and decrease of overall costs related to risk factors
included in the model.
**Standard error of the Estimate.
***The factors advanced disease, haploidentical donor and unrelated donor and age significantly increase the overall costs.
1536 Biol Blood Marrow Transplant 18:1533-1539, 2012S. Matthes-Martin et al.On multivariate analysis, overall costs were signif-
icantly higher in SCT recipients aged .10 years, in
those with advanced disease, and in those who received
a transplantation from an alternative donor source.
Previous SCT, type of graft and conditioning regimen
had no significant impact on costs. The impact of pa-
tient and transplant characteristics on overall costs,
maximum costs and costs per surviving patient is
shown inTable 3. The impact of patient and transplant
characteristics on increase or decrease of overall costs
is shown in Table 4.Pediatric TRM Risk Score
We recently developed and validated a pediatric
TRM risk score in a cohort of 1,364 consecutive pedi-
atric SCT patients that is highly predictive for TRM
and overall survival [15]. This TRM risk score is the
sum of 3 risk factors: age.10 years, advanced disease,
and donor other than matched sibling, resulting in 4
risk groups [15]. In light of the fact that all 3 of these
risk factors correlate with the costs of SCT, we evalu-score 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
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Figure 1. Cost details according to TRM risk score. Costs are given in
V (y-axis). The bars denote the respective TRM risk score (white, 0;
dark, 3).ated whether the TRM risk score might also be predic-
tive of the costs of individual SCTs.
We found a significant correlation between TRM
risk score and the median as well as the maximum
cost of SCT. The median cost of SCT was V89,550
(115,377$) (range, V46,893 (60,417$)-V121,567
(156,367$)) for a TRM risk score of 0, V127,349
(164,087$) (range, V26,897 (34,654$)-V337,658
(434,974$)) for a TRM risk score of 1, V156,578
(201,705$) (range, V58,169 (74,946$)-V537,149
(692,073$)) for a TRM risk score of 2, and V274,915
(354,206$) (range, V109,215 (140,704$)-V601,348
(774,734$)) for a TRM risk score of 3 (P\ .001). The
correlation of costs and TRM risk score was seen not
only for the overall costs but also for the detailed costs
(Figure 1). Mechanical ventilation and hemodialysis
significantly increased the costs of SCT. Of the 141
patients included in the analysis, 27 required admission
to the ICU, including none of the patients with a TRM
risk score of 0, 8 (12%) patients with a score of 1, 10
(23%) patients with a score of 2, and 9 (56%) with
a score of 3.Cost-Effectiveness
To calculate the costs associated with a gain of 1
life-year, the sum of the costs of all SCTs in the respec-
tive patient cohort was divided by the number of
expected long-term survivors and by the estimated
life-years gained. In the calculation of life-years
gained, 2 assumptions were made. Our calculation of
cost-effectiveness was based on the assumption that
pediatric long-term survivors will have a close to nor-
mal life expectancy and close to normal quality of life
[9,18-22]. Median age at SCT was 10 years, which
means that an estimated 60 additional life-years per
survivor are likely to be gained [3].
The second assumption was that the 141 SCTs are
representative. This assumption is based on the fact
that the 141 consecutive SCTs in this analysis are
Table 5. Comparison of Distribution of Patients, TRM, andOverall Survival between the Present Study (n5 141) and the Previous
TRM Risk Score Study (n 5 1,364)
TRM Risk Score
0 1 2 3
Present Previous Present Previous Present Previous Present Previous
Patients 12% 15% 46% 47% 31% 31% 11% 7%
TRM 0% 5% 11% 18% 20% 28% 68% 53%
Overall survival 100% 89% 76% 74% 65% 54% 20% 27%
Biol Blood Marrow Transplant 18:1533-1539, 2012 1537Costs and Cost-Effectiveness of Pediatric SCTcomparable to those in a previous study of 1,364 pedi-
atric SCTs in terms of distribution of patients in the 4
risk groups, TRM, and overall survival (Table 5).
The costs per survivor increased with increasing
TRM risk score, from V89,550 (115,309$) for a score
of 0 to a maximum of V1,216,348 (1,566,240$) for
a score of 3. Restricting the analysis to patients with
malignant diseases, the costs per surviving patient
were V114,239 (147,117$) for a TRM risk score of 0,
V151,224 (194,746$) for a score of 1, V270,512
(348,360$) for a score of 2, and V1,216,348
(1,566,390$) for a score of 3. The costs per patient
and per cured patient according to TRM risk score
are shown in Figure 2. This translates into estimated
costs per life-year gained of V1,553 (2,000$) for
a TRM risk score of 0, V2,545 (3,277$) for a score of
1, V3,857 (4,967$) for a score of 2, and 24,031
(30,904$) for a score of 3.
Cost-Effectiveness Compared with Alternative
Treatment Options
We identified a patient cohort that allows us to
compare the costs of SCT with the costs of an alterna-
tive treatment option without disease-related bias. In
Austria, all children with acute lymphoblastic leukemia
(ALL) are treated with a uniform protocol in which pa-
tients with early bone marrow or combined relapse are
allocated to SCT from matched donors [23].0
200000
400000
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1000000
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1400000
0score 1 2 3
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Figure 2. Total costs in V per patient and per cured patient according
to the TRM risk score. x-axis, TRM risk score; y-axis, costs in V.We calculated the overall treatment costs at our in-
stitution for a previously published patient cohort with
ALL and early isolated and combined bonemarrow re-
lapse (n5 50) who received chemotherapy and did not
undergo SCT [23]. The estimated total (median) costs
for chemotherapy and palliative therapy for the subse-
quent relapse were V111,420 (143,498$) per patient.
Only 2 of the 50 children survived for longer than 10
years, and the median survival of the deceased patients
was 0.3 years. Assuming that long-term survivors of
ALL have a close to normal life expectancy, the extrap-
olated costs of chemotherapy are V43,639 (56,203$)
per life-year gained. In the present study, 32 children
underwent SCT for early relapse of ALL. The median
cost per SCT in this subgroup was V136,975
(176,405$). Twenty-five of the 32 patients were
long-term survivors, which, based on the same as-
sumption, would translate into a median cost of
V2,922 (3,763$) per life-year gained.DISCUSSION
In pediatric SCT, costs per transplantation unit per
year may vary significantly due to low patient numbers
and a heterogeneous patient cohort. On a microeco-
nomic level, the calculation of expected costs per
SCTmight be important for the negotiation of realistic
reimbursement rateswith governmental agencies or in-
surance companies, the allocation of resources, and
cost control [24]. It can also allow evaluation of the
cost-effectiveness of defined changes in transplantation
modalities or supportive care. Our finding that type of
graft and type of conditioning regimen had no impact
on costs is in line with previously published data
[5,7,25]. In contrast to previous studies, we were able
to identify several patient (ie, age and disease status)
and transplantation characteristics (ie, donor type)
associated with significantly increased costs.
Regarding patient characteristics, this association
may be explained by several factors. Overall, SCT
appears to be less costly in pediatric patients than in
adults [26]. Adults usually have more comorbidities,
whichmight affect the costs of SCT regardless of other
patient and transplantation characteristics. The dos-
ages of expensive drugs as well as the need for
1538 Biol Blood Marrow Transplant 18:1533-1539, 2012S. Matthes-Martin et al.transfusional support are correlated with patient
weight, which ranges in pediatric patients from 3 to
.80 kg according to age.Donor search and graft acqui-
sition are more expensive in cases with no available
matched sibling donor; however, these cost differences
may be superseded by other unpredictable factors in
adult SCT [8,27].
Only 5 patients underwent SCT with unrelated
umbilical cord blood (UCB) grafts, a more cost-
intensive treatment [7]. The correlation of costs of
SCT and TRM risk score may differ in recipients of
UCB SCT.
Severe posttransplantation complications and in-
hospital death are associated with higher costs, sug-
gesting that TRM risk score and the costs of SCT
are somehow associated [4,7,8,26,27]. The impact of
in-hospital death on costs might even be higher in pe-
diatric patients than in adult patients, given that very
early TRM has become a rare event in children, and
those who experience TRM require expensive care
for a prolonged period [15,28]. We have shown that
the higher costs associated with a higher TRM risk
score apply to all major cost factors, including length
of hospital stay, use of blood products, individual
medications, and diagnostic procedures. This finding
suggests that the correlation of TRM risk score with
SCT-associated costs can be expected in most pediat-
ric transplantation centers, despite the fact that the ab-
solute costs for the different factors vary from center to
center. In our center, for example, the costs for diag-
nostic procedures are relatively high, because of costly
viral screening and chimerism testing.
In contrast to the microeconomic level, at which
every SCT is reimbursed independent of survival, the
cost-effectiveness of SCT (also taking into account
the costs for deceased patients) is of major importance
on amacroeconomic level. The fact that the same 3 pa-
tient and transplantation characteristics (age, donor
type, and advanced disease) that are highly predictive
for TRM and overall survival had a significant impact
on costs allows us to estimate the cost-effectiveness of
pediatric SCT. Determining the cost-effectiveness of
SCT is hindered by the fact that the actual survival
time for patients with a 5-year disease-free survival
will not be known for another 60 years. Thus, any
cost-effectiveness calculations are based on certain as-
sumptions concerning the number of remaining life-
years. Other uncertainties include the ‘‘hidden costs’’
for pediatric SCT, including out-of-pocket expenses
and foregone income for the parents and the socioeco-
nomic gain in terms of income and taxes of the pediat-
ric survivors [29,30]. Because of these inevitable
uncertainties, we abstained from discounting [31].
Our results are also flawed by the fact that
standardized data on quality of life were not available
for this retrospective analysis [9,32]. However,
several previous studies have reported acceptablequality of life in the majority of long-term SCT survi-
vors [20,28,33-35].
Cost-effectiveness calculations are used mainly to
compare 2 different treatment strategies for a given clin-
ical situation [10]. In the contextof incurablemalignancy,
the discussion of the cost-effectiveness of different ther-
apeutic approaches seems justified [11]. In contrast, pedi-
atric SCT is always a curative approach, and
a comparison with other therapeutic options associated
with significantly lower survival would be ethically unac-
ceptable. Of note, however, pediatric SCT recipients
with early relapse of ALL have significantly higher costs
per life-year saved compared with those who do not un-
dergo SCT. Although the costs associated with single
SCTs increase almost arithmetically with the TRM
risk score, cost-effectiveness decreases dramatically in
the highest risk group, with an estimated cost of at least
V24,000 (30,904$) per life-year gained; nonetheless,
SCT is still cost-effective compared with palliative
treatment.
Compared with the costs of other established ther-
apeutic interventions in patients with nonmalignant
diseases, the costs of SCT appear to be justified, even
in the highest-risk patients. For example, statin treat-
ment formen aged 55 years with a 10-year risk of an ad-
verse vascular event of 10% costs V35,000 (45,070$)
per life-year gained, and the mean annual treatment
cost associated with hemodialysis in Austria is
V40,000 (51,509$) per year [36,37]. Taking into
account the frequently cited thresholds of Anglo-
American health organizations and the discussion con-
cerning novel cancer drugs, the costs of pediatric SCT
are far below the range of acceptable costs and must be
considered cost-effective even in patients considered at
very high risk [1,11,38-40].ACKNOWLEDGMENT
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